These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 23083033)

  • 21. Lupus: novel therapies in clinical development.
    Chugh PK
    Eur J Intern Med; 2012 Apr; 23(3):212-8. PubMed ID: 22385876
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Alpha-actinin-binding antibodies in relation to systemic lupus erythematosus and lupus nephritis.
    Becker-Merok A; Kalaaji M; Haugbro K; Nikolaisen C; Nilsen K; Rekvig OP; Nossent JC
    Arthritis Res Ther; 2006; 8(6):R162. PubMed ID: 17062137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Membrane-bound complement regulatory proteins as biomarkers and potential therapeutic targets for SLE.
    Das N; Biswas B; Khera R
    Adv Exp Med Biol; 2013; 735():55-81. PubMed ID: 23402019
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levels of transforming growth factor-beta are low in systemic lupus erythematosus patients with active disease.
    Becker-Merok A; Eilertsen GØ; Nossent JC
    J Rheumatol; 2010 Oct; 37(10):2039-45. PubMed ID: 20682675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-lipoprotein lipase antibodies: a new player in the complex atherosclerotic process in systemic lupus erythematosus?
    de Carvalho JF; Borba EF; Viana VS; Bueno C; Leon EP; Bonfá E
    Arthritis Rheum; 2004 Nov; 50(11):3610-5. PubMed ID: 15529371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum neopterin, tumor necrosis factor-alpha and soluble tumor necrosis factor receptor II (p75) levels and disease activity in Egyptian female patients with systemic lupus erythematosus.
    Mahmoud RA; El-Gendi HI; Ahmed HH
    Clin Biochem; 2005 Feb; 38(2):134-41. PubMed ID: 15642275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study.
    Aringer M; Graninger WB; Steiner G; Smolen JS
    Arthritis Rheum; 2004 Oct; 50(10):3161-9. PubMed ID: 15476222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of the interferon-alpha pathway identifies a subgroup of systemic lupus erythematosus patients with distinct serologic features and active disease.
    Kirou KA; Lee C; George S; Louca K; Peterson MG; Crow MK
    Arthritis Rheum; 2005 May; 52(5):1491-503. PubMed ID: 15880830
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reduced levels of CCL2 and CXCL10 in systemic lupus erythematosus patients under treatment with prednisone, mycophenolate mofetil, or hydroxychloroquine, except in a high STAT1 subset.
    Dominguez-Gutierrez PR; Ceribelli A; Satoh M; Sobel ES; Reeves WH; Chan EK
    Arthritis Res Ther; 2014 Jan; 16(1):R23. PubMed ID: 24460726
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vitamin D deficiency as marker for disease activity and damage in systemic lupus erythematosus: a comparison with anti-dsDNA and anti-C1q.
    Mok CC; Birmingham DJ; Ho LY; Hebert LA; Song H; Rovin BH
    Lupus; 2012 Jan; 21(1):36-42. PubMed ID: 21993384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating levels of beta-chemokines in systemic lupus erythematosus.
    Kaneko H; Ogasawara H; Naito T; Akimoto H; Lee S; Hishikawa T; Sekigawa I; Tokano Y; Takasaki Y; Hirose SI; Hashimoto H
    J Rheumatol; 1999 Mar; 26(3):568-73. PubMed ID: 10090164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serum free light chains as biomarkers for systemic lupus erythematosus disease activity.
    Aggarwal R; Sequeira W; Kokebie R; Mikolaitis RA; Fogg L; Finnegan A; Plaas A; Block JA; Jolly M
    Arthritis Care Res (Hoboken); 2011 Jun; 63(6):891-8. PubMed ID: 21312346
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinico-biological issues of systemic lupus erythematosus patients].
    Belibou IC; Ancuţa C; Miu S; Ancuţa E; Păstrăguş C; Chirieac R
    Rev Med Chir Soc Med Nat Iasi; 2012; 116(1):83-9. PubMed ID: 23077877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum and urinary cytokine levels of SLE patients.
    Brugos B; Vincze Z; Sipka S; Szegedi G; Zeher M
    Pharmazie; 2012 May; 67(5):411-3. PubMed ID: 22764573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker.
    Simón JA; Cabiedes J; Ortiz E; Alcocer-Varela J; Sánchez-Guerrero J
    Rheumatology (Oxford); 2004 Feb; 43(2):220-4. PubMed ID: 13130152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 'Not only...but also': factors that contribute to accelerated atherosclerosis and premature coronary heart disease in systemic lupus erythematosus.
    Bruce IN
    Rheumatology (Oxford); 2005 Dec; 44(12):1492-502. PubMed ID: 16234277
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.
    Kalunian KC; Chatham WW; Massarotti EM; Reyes-Thomas J; Harris C; Furie RA; Chitkara P; Putterman C; Gross RL; Somers EC; Kirou KA; Ramsey-Goldman R; Hsieh C; Buyon JP; Dervieux T; Weinstein A
    Arthritis Rheum; 2012 Dec; 64(12):4040-7. PubMed ID: 22932861
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-nucleosome antibodies as a disease marker in systemic lupus erythematosus and its correlation with disease activity and other autoantibodies.
    Pradhan VD; Patwardhan MM; Ghosh K
    Indian J Dermatol Venereol Leprol; 2010; 76(2):145-9. PubMed ID: 20228543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lymphocytotoxic antibodies in systemic lupus erythematosus are associated with disease activity irrespective of the presence of neuropsychiatric manifestations.
    Magalhães MB; da Silva LM; Voltarelli JC; Donadi EA; Louzada-Junior P
    Scand J Rheumatol; 2007; 36(6):442-7. PubMed ID: 18092265
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway.
    Higgs BW; Liu Z; White B; Zhu W; White WI; Morehouse C; Brohawn P; Kiener PA; Richman L; Fiorentino D; Greenberg SA; Jallal B; Yao Y
    Ann Rheum Dis; 2011 Nov; 70(11):2029-36. PubMed ID: 21803750
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.